<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00897039</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000491440</org_study_id>
    <secondary_id>SEG-20060042</secondary_id>
    <secondary_id>SEG-IRB-1075624</secondary_id>
    <nct_id>NCT00897039</nct_id>
  </id_info>
  <brief_title>Laboratory Study in Predicting Tumor Response to Chemotherapy in Patients With Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer</brief_title>
  <official_title>Application of the Microculture Kinetic (MiCK) Assay for Apoptosis to Testing Drug Sensitivity of Ovarian, Fallopian and Primary Peritoneal Adenocarcinomas</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Southeastern Gynecologic Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Collecting samples of tissue from patients with cancer to study in the laboratory
      may help doctors predict how well patients will respond to treatment with certain
      chemotherapy drugs and plan the best treatment.

      PURPOSE: This laboratory study is looking at tumor tissue samples to predict response to
      chemotherapy in patients with ovarian cancer, fallopian tube cancer, or primary peritoneal
      cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Evaluate the ability of the microculture kinetic (MiCK) assay to predict the outcome of
           patients with ovarian, fallopian tube, or primary peritoneal adenocarcinoma treated with
           first-line chemotherapy.

        -  Evaluate the ability of the MiCK assay to guide chemotherapy in a third-line, refractory
           treatment setting (exclusive of anti-vascular endothelial growth factor) in these
           patients.

      OUTLINE: Patients are stratified according to prior chemotherapy (no [stratum I] vs yes
      [stratum II]).

      Tumor tissue and/or effusion specimens are collected at baseline. Specimens are examined by
      the microculture kinetic (MiCK) assay and immunocytochemical or flow cytometry assay.

      MiCK assay results do not influence treatment for stratum I patients. Stratum II patients may
      receive treatment based on MiCK assay results for tumor sensitivity to specific chemotherapy
      drugs.

      PROJECTED ACCRUAL: A total of 60 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <primary_outcome>
    <measure>Correlation of a statistically significant discriminator of sensitivity with complete response rate</measure>
  </primary_outcome>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Fallopian Tube Cancer</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Primary Peritoneal Cavity Cancer</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>flow cytometry</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunohistochemistry staining method</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Pathologically confirmed adenocarcinoma of 1 of the following types:

               -  Ovarian

               -  Primary peritoneal

               -  Fallopian tube

          -  Must meet 1 of the following criteria:

               -  De novo malignancy with no prior chemotherapy

               -  Advanced refractory malignancy with â‰¤ 2 standard chemotherapy treatment protocols

          -  Tumor must be accessible for biopsy or drainage of effusions

          -  Chemotherapy is considered a treatment option

          -  No symptomatic or uncontrolled parenchymal brain metastases

          -  No meningeal metastasis

        PATIENT CHARACTERISTICS:

          -  Not pregnant

          -  Negative pregnancy test

          -  Fertile patients must agree to use effective contraception

        PRIOR CONCURRENT THERAPY:

          -  See Disease Characteristics
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir D. Kravtsov, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Pierian Biosciences</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Matthew O. Burrell, MD</last_name>
    <affiliation>Southeastern Gynecologic Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Southeastern Gynecologic Oncology, LLP - Northside</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30342</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Office - Southeastern Gynecologic Oncology, LL</last_name>
      <phone>678-420-4154</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 9, 2009</study_first_submitted>
  <study_first_submitted_qc>May 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 12, 2009</study_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2013</last_update_posted>
  <keyword>ovarian serous cystadenocarcinoma</keyword>
  <keyword>ovarian undifferentiated adenocarcinoma</keyword>
  <keyword>recurrent ovarian epithelial cancer</keyword>
  <keyword>ovarian clear cell cystadenocarcinoma</keyword>
  <keyword>ovarian endometrioid adenocarcinoma</keyword>
  <keyword>ovarian mucinous cystadenocarcinoma</keyword>
  <keyword>stage IA ovarian epithelial cancer</keyword>
  <keyword>stage IB ovarian epithelial cancer</keyword>
  <keyword>stage IC ovarian epithelial cancer</keyword>
  <keyword>stage IIA ovarian epithelial cancer</keyword>
  <keyword>stage IIB ovarian epithelial cancer</keyword>
  <keyword>stage IIC ovarian epithelial cancer</keyword>
  <keyword>stage IIIA ovarian epithelial cancer</keyword>
  <keyword>stage IIIB ovarian epithelial cancer</keyword>
  <keyword>stage IIIC ovarian epithelial cancer</keyword>
  <keyword>recurrent primary peritoneal cavity cancer</keyword>
  <keyword>stage IA primary peritoneal cavity cancer</keyword>
  <keyword>stage IB primary peritoneal cavity cancer</keyword>
  <keyword>stage IC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIC primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIA primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIB primary peritoneal cavity cancer</keyword>
  <keyword>stage IIIC primary peritoneal cavity cancer</keyword>
  <keyword>recurrent fallopian tube cancer</keyword>
  <keyword>stage IA fallopian tube cancer</keyword>
  <keyword>stage IB fallopian tube cancer</keyword>
  <keyword>stage IC fallopian tube cancer</keyword>
  <keyword>stage IIA fallopian tube cancer</keyword>
  <keyword>stage IIB fallopian tube cancer</keyword>
  <keyword>stage IIC fallopian tube cancer</keyword>
  <keyword>stage IIIA fallopian tube cancer</keyword>
  <keyword>stage IIIB fallopian tube cancer</keyword>
  <keyword>stage IIIC fallopian tube cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Fallopian Tube Neoplasms</mesh_term>
    <mesh_term>Peritoneal Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

